Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioventix ( (GB:BVXP) ) has issued an announcement.
Bioventix has disclosed that chief executive Peter Harrison and his wife Abigail have each purchased 1,065 ordinary shares in the company at 1,849 pence per share on 8 April 2026. Following these transactions, Harrison and his closely associated persons now hold a beneficial interest of 306,172 shares, representing about 5.9% of the company’s issued share capital, signalling increased insider alignment with shareholders.
The most recent analyst rating on (GB:BVXP) stock is a Buy with a £1768.00 price target. To see the full list of analyst forecasts on Bioventix stock, see the GB:BVXP Stock Forecast page.
Spark’s Take on BVXP Stock
According to Spark, TipRanks’ AI Analyst, BVXP is a Outperform.
The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).
To see Spark’s full report on BVXP stock, click here.
More about Bioventix
Bioventix plc is a UK-based biotech company specialising in the development and commercial supply of high-affinity monoclonal antibodies used in clinical diagnostic tests. Its products support laboratory assays and immunodiagnostic platforms, positioning the business within the wider medical diagnostics supply chain and serving global in vitro diagnostics manufacturers.
Average Trading Volume: 10,304
Technical Sentiment Signal: Sell
Current Market Cap: £88.82M
For an in-depth examination of BVXP stock, go to TipRanks’ Overview page.